Immune landscape of hepatocellular carcinoma: The central role of TP53-inducible glycolysis and apoptosis regulator
Qiu Lingbing,
Ma Tianyi,
Guo Yunmiao,
Chen Jugao
Affiliations
Qiu Lingbing
Department of Oncology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, 518020, Shenzhen, Guangdong Province, P. R. China
Ma Tianyi
Department of Oncology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, 518020, Shenzhen, Guangdong Province, P. R. China
Guo Yunmiao
Clinical Research Institute of Zhanjiang, Central People’s Hospital of Zhanjiang, Guangdong Medical University Zhanjiang Central Hospital, 236 Yuanzhu Road, 524045, Zhanjiang, Guangdong Province, P. R. China
Chen Jugao
Department of Oncology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, No. 1017, Dongmen North Road, Luohu District, 518020, Shenzhen, Guangdong Province, P. R. China
This study aims to address the substantive issue of lacking reliable prognostic biomarkers in hepatocellular carcinoma (HCC) by investigating the relationship between TP53-inducible glycolysis and apoptosis regulator (TIGAR) and HCC prognosis using The Cancer Genome Atlas database.
